ecNumber*3.4.23.46#specificActivity*-999#specificActivityMaximum*#commentary*homogenous time-resolved fluorescence assay method#organism*Homo sapiens#literature*638906#!ecNumber*3.4.23.46#specificActivity*-999#specificActivityMaximum*#commentary*beta-secretase (BACE1) inhibitors isolated from the methanolic extract of Perilla frutescens characterized, specificity against beta-secretase BACE1 higher than for other enzymes such as alpha-secretase (TACE), acetylcholine esterase (AchE), chymotrypsin, and elastase#organism*Perilla frutescens#literature*683101#!ecNumber*3.4.23.46#specificActivity*-999#specificActivityMaximum*#commentary*acetylation of BACE1 on seven lysine residues of the N-terminus shown, substitution of lysine residues shown to block ability of BACE1 to be acetylated in vivo and in vitro, lysine acetylation of BACE1 shown to be required for stabilization and for leaving the endoplasmic reticulum to move ahead into secretory pathway, model of BACE1 transient lysine acetylation/deacetylation presented#organism*Homo sapiens#literature*683141#!ecNumber*3.4.23.46#specificActivity*-999#specificActivityMaximum*#commentary*identification of a 24-residue peptide corresponding to the C-terminus of BACE1 that binds a single copper atom with high affinity, cytoplasmic domain of BACE1 shown to interact with dedicated copper chaperone for superoxide dismutase 1, reduced activity of superoxide dismutase 1 by overproduction of BACE1 demonstrated, activity of superoxide dismutase 1, cytosolic copper and ectodomain cleavage of amyloid precursor protein APP shown to be linked through BACE1, quaternary protein complex of BACE1 with associated factors proposed#organism*Homo sapiens#literature*683143#!ecNumber*3.4.23.46#specificActivity*-999#specificActivityMaximum*#commentary*overview about dysregulation of BACE1 expression and activity in normal and Alzheimer brains, comparative analyses performed on BACE1 activities and protein levels in control and Alzheimer disease brain summarized, substrate with Swedish mutation of amyloid precursor protein APP and with wild-type amyloid precursor protein APP regarded, different brain regions considered, differences between BACE1 and BACE2 summarized#organism*Homo sapiens#literature*683144#!ecNumber*3.4.23.46#specificActivity*-999#specificActivityMaximum*#commentary*BACE1 inhibitors generated by 9-fluorenylmethoxycarbonyl-solid-phase peptide synthesis methods, characterization of BACE1 inhibitor KMI-574, generation by replacement of acidic tetrazole ring with hydrogen bond acceptor group indicated, potent inhibitory activity in cultured cells as well as in vitro enzymatic assay shown, inhibitory activities summarized#organism*Homo sapiens#literature*683238#!ecNumber*3.4.23.46#specificActivity*-999#specificActivityMaximum*#commentary*generation of selective non-peptidic small molecule inhibitors of BACE1, reagents and synthetic route summarized#organism*Homo sapiens#literature*683244#!ecNumber*3.4.23.46#specificActivity*-999#specificActivityMaximum*#commentary*synthesis, structure and potencies of BACE1 inhibitors shown, inhibitory assays summarized, novel nonpeptidic and small-sized BACE1 inhibitors developed, design of small-sized BACE1 inhibitor 2 possessing heterocyclic ring at the P2 position shown, reagents and conditions summarized, BACE1 inhibitors possessing benzylamino-type groups at the P3 position and their BACE1 inhibitory activities summarized, BACE1 inhibitors with a 5-membered ring at the P3 position and inhibitory activities indicated, molecular surface properties shown#organism*Homo sapiens#literature*683248#!ecNumber*3.4.23.46#specificActivity*-999#specificActivityMaximum*#commentary*basic biology of BACE1 focusing on the regulation, structure and function reviewed, overview about dysregulation of BACE1 in Alzheimer disease, behavioral and physiological alterations of BACE1 knockout mice described, putative function of BACE1 during normal conditions summarized, relationship between key risk factors for Alzheimer disease and the pathogenic alterations in BACE1 observed in the diseased state discussed#organism*Homo sapiens#literature*683380#!ecNumber*3.4.23.46#specificActivity*-999#specificActivityMaximum*#commentary*synthesis, structure and potencies of memapsin 2 inhibitors shown, memapsin 2 enzyme inhibitory and cellular assays described, up to 65% reduction of plasma amyloid-beta peptide in transgenic mice indicated, ligand-binding site interactions indicated by stereoview of X-ray structure#organism*Homo sapiens#literature*683381#!ecNumber*3.4.23.46#specificActivity*-999#specificActivityMaximum*#commentary*synthesis, structure and potencies of memapsin 2 inhibitors shown, up to 65% reduction of plasma amyloid-beta peptide in transgenic mice indicated#organism*Mus musculus#literature*683381#!ecNumber*3.4.23.46#specificActivity*-999#specificActivityMaximum*#commentary*dysregulation of BACE1 expression and activity measured in normal and Alzheimer brains, differences between BACE1 and BACE2 analyzed, kinetics of beta-secretase enzymatic activity in individual normal and Alzheimer brains shown, activity found to be saturable following Michaelis-Menten kinetics, increased Vmax of BACE1 in Alzheimer disease cases not found to be correlated with levels of BACE1, decreased BACE1 and BACE2 levels found to be correlated with severity of neurofibrillary pathology and synaptic loss in Alzheimer disease#organism*Homo sapiens#literature*683469#!ecNumber*3.4.23.46#specificActivity*-999#specificActivityMaximum*#commentary*characterization of structure and regulatory region of the beta-secretase BACE1 promoter, more repetitive elements in BACE1 than in BACE2 identified, regulatory domains of BACE1 promoter shown to be different from those of BACE2, DNA-protein interaction studies performed, BACE1-driven reporter protein expression shown to be higher than those of BACE2, operation of BACE1 through a single transcriptional control site suggested, differences to BACE2 summarized, genomic mapping of BACE1 and BACE2 on chromosome and of functional domains performed#organism*Homo sapiens#literature*683790#!ecNumber*3.4.23.46#specificActivity*-999#specificActivityMaximum*#commentary*oxidative stress measured in cytosolic fractions, antibodies and immunoblot analysis performed, RNA interference and Luciferase reporter gene assay applied, stimulation of BACE1 expression by oxidative stress determined, mechanism shown to require gamma-secretase activity involving the c-jun N-terminal kinase (JNK)/c-jun pathway, inceased BACE1 levels identified in normal cells, but not in cells lacking presenilins or amyloid precursor protein, correlation with activation of JNK and c-jun determined#organism*Mus musculus#literature*683797#!ecNumber*3.4.23.46#specificActivity*-999#specificActivityMaximum*#commentary*structural features of the active form of BACE1 described, regulatory mechanism of enzymatic activity of BACE1 characterized by crystallization, conformation of the flap and subsites that promote substrate binding determined, functionally essential residues and water molecules for key role in the iterative activation of BACE1 shown, dependence of BACE1 activity on dynamics of a catalytically required aspartic acid-bound water molecule BACE1 shown, data refinement and statistics summarized#organism*Homo sapiens#literature*683872#!ecNumber*3.4.23.46#specificActivity*-999#specificActivityMaximum*#commentary*beta2 subunit of voltage-gated sodium channel analyzed as substrate of BACE1, increase of mRNA and protein levels of pore-forming alpha subunit of sodium channel after cleavage observed, regulation of alpha subunit of voltage-gated sodium channel mediated through BACE1, association between BACE1 and cell-surface sodium current densities shown#organism*Homo sapiens#literature*683908#!ecNumber*3.4.23.46#specificActivity*-999#specificActivityMaximum*#commentary*beta2 subunit of voltage-gated sodium channel analyzed as substrate of BACE1, increase of mRNA and protein levels of pore-forming alpha subunit of sodium channel after cleavage observed, regulation of alpha subunit of voltage-gated sodium channel mediated through BACE1, association between BACE1 and cell-surface sodium current densities shown#organism*Mus musculus#literature*683908#!ecNumber*3.4.23.46#specificActivity*-999#specificActivityMaximum*#commentary*genetic deletion of BACE1 causes hypomyelination, elevated pain sensitivity and reduced grip strength shown in BACE1-null mice, neuregulin-1 expression increased and cleavage products and phosphorylated AKT protein kinase shown to be decreased in BACE1-null mice, neuregulin-1 cleavage by BACE1 shown, processed neuregulin-1 regulates myelination by means of phosphorylation of AKT protein kinase in myelin-forming cells#organism*Mus musculus#literature*683911#!ecNumber*3.4.23.46#specificActivity*-999#specificActivityMaximum*#commentary*increased BACE1 activity determined in hippocampal CA1 and CA3 regions of mice tretated by combination of ovariectomy and chronic stress, condition shown to evoke an impairment of hippocampus-dependent memory, association between stressful life after menopause and Alzheimer disease-related molecules suggested, BACE1 discussed as the most sensitive molecule#organism*Mus musculus#literature*683928#!ecNumber*3.4.23.46#specificActivity*0.01#specificActivityMaximum*#commentary*using Z-Val-Asn-Leu-7-amido-4-methylcoumarin as substrate#organism*Mus musculus#literature*698870#!ecNumber*3.4.23.46#specificActivity*0.02#specificActivityMaximum*#commentary*#organism*Mus musculus#literature*698870#